Class I phosphoinositide 3-kinase (PI3K) is a dimeric enzyme, consisting of a catalytic and a regulatory subunit. The catalytic subunit occurs in four isoforms designated as p110a, p110b, p110c and p110d. These isoforms combine with several regulatory subunits; for p110a, b and d, the standard regulatory subunit is p85, for p110c, it is p101. PI3Ks play important roles in human cancer. PIK3CA, the gene encoding p110a, is mutated frequently in common cancers, including carcinoma of the breast, prostate, colon and endometrium. Eighty percent of these mutations are represented by one of the three amino-acid substitutions in the helical or kinase domains of the enzyme. The mutant p110a shows a gain of function in enzymatic and signaling activity and is oncogenic in cell culture and in animal model systems. Structural and genetic data suggest that the mutations affect regulatory inter-and intramolecular interactions and support the conclusion that there are at least two molecular mechanisms for the gain of function in p110a. One of these mechanisms operates largely independently of binding to p85, the other abolishes the requirement for an interaction with Ras. The non-a isoforms of p110 do not show cancerspecific mutations. However, they are often differentially expressed in cancer and, in contrast to p110a, wild-type non-a isoforms of p110 are oncogenic when overexpressed in cell culture. The isoforms of p110 have become promising drug targets. Isoform-selective inhibitors have been identified. Inhibitors that target exclusively the cancer-specific mutants of p110a constitute an important goal and challenge for current drug development.
Introduction
This contribution will present a brief review of class I phosphoinositide 3-kinases (PI3Ks) and their oncogenic activities, focusing on cancer-specific mutations and on differential expression of the four catalytic subunits of this enzyme family.
Class I PI3Ks phosphorylate phosphatidylinositol 4,5 bisphosphate (PIP 2 ) at the 3 position of the inositol ring. The product, phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ), functions as a second cellular messenger that controls cell growth, survival, proliferation, motility and morphology (Vanhaesebroeck and Waterfield, 1999; Katso et al., 2001; Vanhaesebroeck et al., 2001; Cantley, 2002; Vivanco and Sawyers, 2002; Okkenhaug and Vanhaesebroeck, 2003; Deane and Fruman, 2004; Bader et al., 2005; Engelman et al., 2006; Hawkins et al., 2006) . The phosphatase PTEN (phosphatase and TENsin homolog deleted on chromosome 10) hydrolyzes PIP 3 to PIP 2 , thus acting as the catalytic antagonist of PI3K (Maehama and Dixon, 1998; Myers et al., 1998; Stambolic et al., 1998) . Mutational activation and overexpression of class I PI3K and genetic or epigenetic inactivation of PTEN result in enhanced PI3K signaling, which is associated with oncogenic cellular transformation and cancer (Ali et al., 1999; Maehama et al., 2001; Simpson and Parsons, 2001; Cantley, 2002; Wishart and Dixon, 2002; Eng, 2003; Bachman et al., 2004; Broderick et al., 2004; Campbell et al., 2004; Fruman, 2004; Leslie and Downes, 2004; Samuels et al., 2004; Bader et al., 2005; Hartmann et al., 2005; Lee et al., 2005; Levine et al., 2005; Li et al., 2005; Saal et al., 2005; Wang et al., 2005; Kang et al., 2005b; Cully et al., 2006; Vogt et al., 2007; Salmena et al., 2008) . Because of the enzymatic antagonism of PI3K and PTEN, it is tempting to equate loss of PTEN with gain in PI3K function. However, there is mounting evidence that a loss of PTEN results in cellular changes that are quite different from those induced by a gain of function in PI3K (Blanco-Aparicio et al., 2007) . The enzymatic antagonism is not the only determining factor that characterizes the balance of PTEN and PI3K in the cell. The cellular distribution of the two proteins is different, and these differences can be enhanced by external and internal stimuli. Interaction with other proteins could also gravely affect the balance between PTEN and PI3K. Tumors that have lost PTEN often show drug sensitivities that are different from those that have a direct gain of PI3K function (Salmena et al., 2008) .
Only class I PI3Ks are involved in cancer; there are no data linking class II PI3Ks or class III PI3K (Vps34p) to oncogenesis. This fact probably reflects the different product and substrate specificities of the three classes of PI3K. Only class I PI3Ks can use PIP 2 to generate PIP 3 , class II PI3Ks produce the 3,4-bisphosphate and the 3-monophosphate of inositol lipids, and class III can only make the 3-monophosphate. PIP 3 is a critical component in the control of cell growth and replication, and the ability to produce this important second messenger molecule confers oncogenic potential to the lipid kinase. Class I PI3Ks have both lipid and protein kinase activities . Genetic experiments have shown that lipid kinase is essential for oncogenic activity; p110 engineered to have only protein kinase activity is nononcogenic . Whether protein kinase plays a role in conjunction with lipid kinase is not known.
The canonical PI3K signaling pathway
In normal cells, the activity of class I PI3Ks is tightly controlled. Upstream signals recruit the cytosolic PI3Ks to the plasma membrane. This relocation is mediated by interactions with receptor tyrosine kinases (Skolnik et al., 1991) or G-protein-coupled receptors (Stephens et al., 1994) . Interaction with Ras also contributes to the activation of PI3K (Rodriguez-Viciana et al., 1994 Chan et al., 2002 ; Figure 1 ). The product of class I PI3K, PIP 3 , recruits proteins that contain a pleckstrin homology domain to cellular membranes (Corvera and Czech, 1998) . Among these are the serine-threonine kinase Akt (cellular homolog of murine thymoma virus Akt8 oncoprotein) as well as its activating kinase PDK1 (3-phosphoinositide-dependent kinase 1). PDK1 phosphorylates and thereby activates Akt at threonine 308 (Alessi et al., 1997) . Signals originating from Akt control the initiation of protein synthesis through a cascade of interactions that proceeds through the TSC (tuberous sclerosis complex), Rheb (Ras homolog enriched in brain) and TOR (target of rapamycin) to two critical downstream targets, S6K (p70 S6 kinase) and 4EBP (eukaryotic initiation factor 4E-binding protein; Inoki et al., 2002 Inoki et al., , 2003 Garami et al., 2003; Tee et al., 2003; Zhang et al., 2003; Bader and Vogt, 2004) . Akt signals also regulate transcription, inducing phosphorylation-dependent degradation of FOXO1 (forkhead box O transcription factor; Biggs et al., 1999; Brunet et al., 1999; Kops et al., 1999; Takaishi et al., 1999; Tang et al., 1999) and inactivation of GSK3b (glycogen synthase kinase-3b; Cross et al., 1995) . Important targets of FOXO1 are the growthattenuating p27(Kip1; Medema et al., 2000) and p21(Cip1; Seoane et al., 2004) and proapoptotic BIM (Bcl-2 interacting mediator of cell death) proteins (Stahl et al., 2002; Gilley et al., 2003; Arden, 2004) . GSK3b regulates the potentially oncogenic transcription factors Jun (cellular homolog of the Jun oncoprotein of avian retrovirus ASV17) and Myc (cellular homolog of the avian myelocytoma retroviral oncogene; Nikolakaki et al., 1993; de Groot et al., 1993; Sears et al., 2000; Gregory et al., 2003; Wei et al., 2005) . In a positive feedback loop, TOR, in complex with the Rictor (rapamycin-insensitive companion of TOR) protein Figure 1 The canonical PI3K signaling pathway. PI3Ks can be activated by RTKs (with or without adaptors such as IRS1) or GPCRs. Ras is an additional positive regulator of PI3K, probably by facilitating membrane localization. The phosphatase PTEN dephosphorylates the product of PI3K, PIP 3 at the 3 position and thus acts as the exact enzymatic antagonist of PI3K. PIP 3 initiates downstream signaling by recruiting the serine-threonine kinases Akt and PDK1. PDK1 phosphorylates and thereby activates Akt. Three major signaling branches originate from Akt. Akt-mediated phosphorylation of GSK3b and of FOXO directly and indirectly controls transcriptional activities and cellular growth and survival (blue icons). The signal proceeding through the TSC complex, RHEB and TOR affects primarily protein synthesis (beige icons). A positive feedback loop extends from the TOR-RICTOR complex to Akt, resulting in additional activating phosphorylation of Akt. A negative feedback loop consists of the S6K-mediated phosphorylation of IRS1. GPCRs, G-protein-coupled receptors; RTKs, receptor tyrosine kinases; Raf, V-Raf murine leukemia viral oncogene homolog; MEK, Map/Erk kinase; ERK, extracellular signal-regulated kinase; Map, mitogen-activated protein.
phosphorylates and thereby additionally activates Akt at serine 473 (Sarbassov et al., 2005) . S6K can introduce an inhibitory phosphorylation on IRS1 (insulin receptor substrate 1), mediating a negative feedback loop (Harrington et al., 2004) . Ras is also linked to the PI3K pathway. Activated Ras enhances the activities of PI3K; in turn, the product of PI3K, PIP 3 , stimulates Ras activation (Rodriguez-Viciana et al., 1994 Chan et al., 2002) . The overall effect of the combined PI3K signals is to enhance the stimulation of cellular replication and survival and to reduce the growth inhibition and apoptosis.
Class I PI3Ks are heterodimeric proteins that consist of a catalytic subunit and a regulatory subunit, also referred to as an adaptor (Figure 2 ). There are four isoforms of the catalytic subunit: p110a, p110b, p110d and p110g. They share the same domain composition: an amino-terminal adaptor-binding domain (ABD) that provides the principal interaction surface with the regulatory subunit, a Ras-binding domain (RBD) that mediates the interaction between p110 and Ras-GTP and contributes to the stimulation of PI3K and to the Ras-driven signaling pathway, a C2 (protein-kinase-C homology-2) domain with affinity for lipid membranes, a helical domain acting as a scaffold for other domains of p110 and a carboxyl-terminal kinase domain (Walker et al., 1999) . Class I PI3Ks are further subdivided according to their regulatory subunits (Vanhaesebroeck et al., 1997a) . Class IA, encompassing p110a, p110b and p110d associates with the regulatory subunits p85a, p85b, p55a, p55g and p50a. Class IB, consisting only of p110g, binds the regulatory subunits p101, p84 and p87PIKAP. The representative regulatory subunit, p85a, contains several modular protein-protein interaction domains: a Src-homology 3 (SH3) domain, a breakpoint clustered homology (BH) domain, two Srchomology 2 (SH2) domains, and an inter-SH2 (iSH2) domain. The iSH2 domain is the primary p110-binding domain Klippel et al., 1994) . Regulatory subunits link p110 to upstream signals, interacting with receptor tyrosine kinases and Gprotein-coupled receptors . In the absence of upstream signals, the regulatory subunits stabilize p110 and suppress its catalytic activities (Yu et al., 1998; Luo et al., 2005) .
Cancer-specific mutations in PIK3CA
The gene coding for p110a, PIK3CA, is mutated in various human cancers Samuels and Ericson, 2006) . The mutations are nonsynonymous, arising from single-nucleotide substitutions. They occur in around 30% of several common cancers, including carcinoma of the breast, colon, endometrium and prostate (Catalogue of Somatic Mutations in Cancer, http://www.sanger.ac.uk/genetics/CGP/cosmic). These cancers carry a single p110a mutation, and 80% of the mutated proteins contain one of three 'hot spot' mutations. Two of these hot spot mutations map to the helical domain of p110a, and the third resides in the kinase domain. The hot spot mutations induce a gain of function in p110a. The lipid kinase activity of the mutant protein is significantly upregulated Ikenoue et al., 2005; Kang et al., 2005a) . Mutant-expressing cells show constitutive downstream signaling detectable by the elevated phosphorylation of Akt, S6K, 4EBP and GSK3b. p110a carrying one of the hot spot mutations shows oncogenic activity. It can transform primary fibroblasts in culture, induce anchorage-independent growth and cause tumors in animal model systems (Ikenoue et al., 2005; Isakoff et al., 2005; Zhao et al., 2005; Kang et al., 2005a; Bader et al., 2006) . This oncogenic potential probably contributes to the neoplastic phenotype of the human cancer cells carrying mutant p110a; the mutations can therefore be regarded as 'driver' mutations. The clustering of p110a mutations in hot spots suggests that the mutations provide a selective growth advantage to the cell. In addition to the three hot spot mutations, which account for four fifths of the p110a mutations, numerous different rare cancerspecific mutations have been identified (for selected examples, see Figure 3 ). They are widely distributed over the coding sequence and occur in all domains of p110a except the RBD. Most of these rare mutations also show a gain of function (Ikenoue et al., 2005; Gymnopoulos et al., 2007) . However, quantitative measurements of oncogenic activity show that these rare mutants are far less potent than the hot spot mutants. This lower level of oncogenic activity may translate into a weaker selective advantage for the mutant-carrying cell and may explain the rarity of these marginally oncogenic mutations. A recurring theme in the gain-of-function mutations of p110a is a substitution of an acidic or neutral residue with a basic residue and location of the substituted residue on the surface of the protein. Indeed, some of the engineered point mutations of p110a that meet these criteria show a gain of function .
Structural data
The X-ray crystal structure of p110a in complex with a portion of p85a has been solved (Huang et al., 2007 ,
Figure 2 PI3K is a dimeric enzyme. The figure shows the domain structure and domain interaction map of the standard regulatory subunit, p85 and the catalytic subunit, p110 (Walker et al., 1999; Pacold et al., 2000; Shekar et al., 2005; Huang et al., 2007; Miled et al., 2007) . PI3K, phosphoinositide 3-kinase.
PI3K in oncogenic cellular transformation L Zhao and PK Vogt 2008). The data show that the ABD of p110a not only binds to the iSH2 domain of p85 (the region responsible for high-affinity binding between p85 and p110), but also interacts with the kinase domain and a linker region between ABD and RBD. R38 and R88 of p110a form hydrogen bonds with Q738, D743 and D746 of the N-terminal lobe of the kinase domain. The rare cancerspecific mutations, R38H, R38C and R88Q possibly disrupt these interactions, resulting in a conformational change of the kinase domain. An ABD deletion mutant of wild-type p110a shows the enhanced lipid kinase activity compared to its full-length counterpart Zhao and Vogt, 2008) . This increase in activity may be due to the loss of an inhibitory interaction between ABD and the kinase domain of p110a, or it may reflect a relief of the inhibition that is caused by the binding of the N-SH2 (N-terminal SH2) domain of p85 to the helical domain of p110 (see below). Deletion of part of the p85-binding domain in wild-type p110a also reveals a low level of oncogenic transforming activity that is readily demonstrable in cell culture (Zhao and Vogt, 2008 ).
The C2 domain has been postulated to facilitate the recruitment of p110 to the plasma membrane (Nalefski and Falke, 1996; Newton and Johnson, 1998; Rizo and Sudhof, 1998) . This function is evident in the crystal structure of p110g (Walker et al., 1999) . Positively charged amino acids are critically involved in membrane binding (Heo et al., 2006) . Cancer-specific mutations (N345K and C420R) in the C2 domain of p110a increase the positive surface charge of the domain and were thought to mediate improved binding to the cell membrane, making lipid kinase activity independent of signals transmitted through the regulatory subunit . However, in the cocrystal structure of p110a and p85, N345 of p110a forms a hydrogen bond with N564 and D560 in the iSH2 domain of p85. Therefore, N345K is likely to disrupt this interaction of the C2 and iSH2 domains and thus alter the regulatory effect of p85 on p110a (Huang et al., 2007) . The electron density of the C420 residue in the C2 domain of p110a is not seen in the cocrystal structure. The C420R mutation may function to increase the affinity of p110a for lipid membranes as previously PI3K in oncogenic cellular transformation L Zhao and PK Vogt proposed . Another C2 domain mutation, E453Q, also disrupts the interaction of the C2 domain with iSH2, similar to the N345K mutation (Huang et al., 2007) .
Biochemical and structural modeling studies provide evidence for an interaction between the helical domain of p110a and the N-SH2 domain of p85 (Shekar et al., 2005; Miled et al., 2007; Wu et al., 2007) . In the cocrystal structure of p110a/p85, the N-SH2 domain is not highly ordered. However, a structural model can be generated, if biochemically identified interactions are taken into account. In this model, the N-SH2 domain of p85 binds to the interface between the kinase and the helical domains of p110a (Huang et al., 2007) . These interactions may be responsible for the p85-induced inhibition of p110a. The helical domain mutations (E542K and E545K) could interfere with this p85-p110a interaction and thus could relieve the inhibition. The phosphorylated insulin receptor substrate activates the lipid kinase activity of wild-type p110a, presumably by engaging the N-SH2 domain of p85 and thus lifting the inhibitory hold of N-SH2 on the helical domain. This activation is not seen in the helical domain mutants suggesting that the inhibitory interaction with the N-SH2 domain of p85 has been weakened or interrupted by the mutations (Carson et al., 2008) . However, helical domain mutations that carry an ABD truncation show significantly higher oncogenic activity than the truncated wild-type p110a (Zhao and Vogt, 2008) . As both have lost p85 binding, the difference in oncogenic potency suggests an effect of the helical domain mutations that goes beyond interference with p85 binding. The relevant intra-and intermolecular interactions are schematically summarized in Figure 2 .
The genetics of cancer-specific mutations in PIK3CA
Genetic experiments provide insight into the molecular mechanisms of mutant-induced gain of function in p110a Kang et al., 2005a; Liu and Roberts, 2006; Zhao and Vogt, 2008) . The location of the hot spot mutations in two different domains of the protein, E542K and E545K in the helical and H1047R in the kinase domain, suggests that they operate by different mechanisms. This proposal is supported by the observation that combining helical and kinase domain hot spot mutations in the same molecule has a strongly synergistic effect on downstream signaling and on oncogenic potency. The double mutant, E545K/ H1047R, has also been found in human cancer . The case for mechanistic differences between helical and kinase domain mutations is further strengthened by the interactions with p85 and Ras (Zhao and Vogt, 2008) . A truncation of the p85-binding domain that eliminates the interaction with p85 does not silence oncogenic and signaling activities of the helical domain mutants, but completely abolishes oncogenicity in the kinase domain mutant. Curiously, the thus incapacitated kinase domain mutant still signals through Akt and TOR, albeit at lower levels. Disabling the Rasp110a interaction by the K227E mutation in the RBD has the opposite effect on the hot spot mutants of p110a. Interaction of GTP-bound Ras with wild-type p110a is known to augment the activity of p110a (Chan et al., 2002) , possibly by inducing a conformational change in the substrate-binding site (Pacold et al., 2000) . In turn, PI3K is an important Ras effector, mediating the proliferative and survival functions of Ras (Rodriguez-Viciana et al., 1994 . Introducing the Rasbinding mutation into the hot spot mutants causes a complete loss of oncogenic potency in the helical domain mutations together with a cessation of signaling, whereas the kinase domain mutant is unaffected by the absence of Ras-binding (Figures 3 and 4) . The kinase domain mutant is even able to rescue helical domain mutants that were incapacitated by the absence of Rasbinding, restoring oncogenic and signaling activities to the synergistic levels seen with helical-kinase domain double mutants. The kinase domain mutation maps close to the activation loop and may affect the conformation of the loop, altering the interaction with the substrate (Huang et al., 2007 (Huang et al., , 2008 . Previous structural studies on the p110g-Ras complex have demonstrated a change in the conformation of the substrate-binding site as a result of the interaction with Ras (Pacold et al., 2000) . The kinase domain mutation H1047R may induce a similar conformational change in the absence of Ras and thus gain Ras independence. The data on p85 and Ras interaction strongly support the existence of two distinct molecular mechanisms for the mutation-induced gain of function in p110a. The data are compatible with the suggestion that the helical domain mutations lift the inhibitory interaction between N-SH2 of p85 and the helical domain of hot spot mutants of p110a and that the kinase domain mutation mimics the conformational change that is triggered by the interaction with Ras (Zhao and Vogt, 2008) . These straightforward interpretations ascribe the effect of the mutations in the p85 and Ras interacting domains to the Figure 4 The interactions with p85 and with Ras define two distinct molecular mechanisms for the gain of function seen in the hot spot mutations in p110a. The helical domain mutations are largely but not completely independent of binding to p85 but require the interaction with Ras. The kinase domain mutation completely depends on the interaction with p85 but is not affected by a loss of Ras binding. However, the kinase domain mutation still shows residual signaling activity in the absence of p85 binding.
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L Zhao and PK Vogt specific elimination of p85 and Ras binding, respectively. However, the possibility that these mutant effects are caused by some conformational change that is independent of the targeted protein-protein interactions has not been ruled out. For instance, the cocrystal structure of p110a and p85 also reveals an unexpected interaction between p85-binding domain and kinase domain, which would be affected by the truncation of the p85-binding region (Huang et al., 2007) . The ultimate test of these ideas will be the cocrystal structure of mutant p110a bound to the full-length p85 regulatory subunit.
The non-a isoforms of class I PI3K
Although the four isoforms of class I PI3K have identical enzymatic activities, they have different, nonredundant cellular functions. Their patterns of expression are distinct, ubiquitous for the p110a and p110b isoforms and largely leukocyte-specific for p110g and p110d (Vanhaesebroeck et al., 1997b; Sawyer et al., 2003) . Genetic inactivation of p110a and p110b in mice leads to early embryonic lethality (Bi et al., 1999 (Bi et al., , 2002 ; p110g and p110d knockout mice are viable but show defective immune responses (Hirsch et al., 2000; Li et al., 2000; Sasaki et al., 2000; Clayton et al., 2002; Jou et al., 2002; Laffargue et al., 2002; Okkenhaug et al., 2002; Rodriguez-Borlado et al., 2003; Ali et al., 2004) . Conditional and tissue-specific mutations of the p110 isoforms and experiments with isoform-specific antibodies have generated a steadily increasing catalog of diverse isoform-specific activities (Vanhaesebroeck et al., , 2005 Hooshmand-Rad et al., 2000; Bony et al., 2001; Leverrier et al., 2003; Yip et al., 2004; Foukas et al., 2006; Suire et al., 2006; Ji et al., 2007; Ali et al., 2008; Graupera et al., 2008) . The general conclusions emerging from this work place p110g and d firmly in the realm of the immune system, assign p110a to cell growth and reveal an interesting connection between p110b and blood clotting (Ono et al., 2007; van der Meijden et al., 2008) . Class I p110a has attracted much attention because of its involvement in cancer, documented by the frequent occurrence of gain-offunction, cancer-specific mutations. No such cancerspecific mutations have been identified in the non-a isoforms. Yet there is evidence that non-a isoforms of p110 are involved in the development and progression of malignancies. Consistent overexpression of p110d is seen in acute myeloblastic leukemia (Sujobert et al., 2005) . Inhibitors of p110d specifically interfere with the growth of the leukemic cells, suggesting that p110d can function as an oncoprotein (Sadhu et al., 2003) . Elevated expression of p110g is observed in chronic myeloid leukemia (Skorski et al., 1997; Hickey and Cotter, 2006) . Further data suggest a role of non-a isoforms in cancers PI3K in oncogenic cellular transformation L Zhao and PK Vogt of the bladder, brain and colon (Benistant et al., 2000; Mizoguchi et al., 2004; Knobbe et al., 2005) . Overexpression of non-a isoforms in cancer is significant in view of observations in cell culture. Unlike wild-type p110a, which lacks oncogenic activity when expressed in primary fibroblasts, the wild-type non-a isoforms are oncogenic. This surprising activity of p110b, g and d was first documented in avian cells , but has now been observed in rodent cells as well (Ueno and Vogt, unpublished) . The absence of cancer-specific mutations in the non-a isoforms may therefore reflect an inherent oncogenic potential that can be activated by differential expression in the absence of mutation.
A study of cells transformed by p110 isoforms has revealed striking isoform-specific activities that group p110b and p110g together, placing them apart from p110a and p110d ( Figure 5 ; Denley et al., 2008) . In PI3K-transformed cells, wild-type p110d signals constitutively as does the H1047R mutant of p110a. Transformation by p110b and p110g does not result in constitutive downstream signaling. This deficiency can be remedied by the addition of a myristylation signal to p110b and p110g, which also results in an enhancement of oncogenic activity ( Figure 5 ). Additional criteria also show similarities between p110b and p110g: oncogenicity and signaling of these isoforms require interactions with Ras. The disabling mutation of the RBD K227E eliminates transforming and signaling activities of p110b and p110g. In contrast, the activities of p110a H1047R and of wild-type p110d are not affected by this mutation in the RBD. Again, myristylation of p110b and p110g can substitute for Ras binding, restoring oncogenic and signaling potential (Figure 6a ). This observation suggests that an essential function of Ras in PI3K signaling is the recruitment of p110b and p110g to the cell membrane. This recruitment function of Ras may also explain the Ras independence of p110d. p110d has a unique accumulation of basic residues in its C2 domain, which probably mediate a direct interaction with the cell membrane. Mutating these basic residues results in an inactive protein. The dependence of p110b and p110g on Ras is also seen in their sensitivity to inhibitors of the MAP kinase (mitogen-activated protein kinase) pathway. The Raf inhibitor BAY43-9006 and the MEK1/2 inhibitor U0126 interfere with oncogenicity and signaling of p110b and p110g (Figure 6b ).
Evolving small molecule inhibitors of p110
The distinctive properties of the p110 isoforms lead to the question of small molecule inhibitors and their specificity. The standard PI3K inhibitors for experimental work, wortmannin and LY294002, are not isoform specific. However, there are several inhibitors that show significant selectivity for one of the isoforms (Denley et al., 2008;  Figure 7 ). However, they are ATPcompetitive inhibitors, and because ATP-binding pockets of different kinases are structurally similar, such inhibitors usually show activities against several kinases. Of the ones shown in the figure, PI 103 also inhibits TOR, and TGX221 is effective against class III PI3K. All four p110 isoforms are promising targets for small molecule inhibitors, each isoform is linked to a specific set of clinical indications. The identification and development of such inhibitors with drug-like properties and therapeutic potential has proceeded at a rapid pace in recent years (for example, see Knight et al., 2006; Knight and Shokat, 2007; Raynaud et al., 2007; Yaguchi et al., 2006; Patent 2007-EP4501; Patent 2007-US9866; Patent 2006-GB4554; Patent 2007-US18057 and Patent 2007-EP50618) . The success of these efforts and the initiation of clinical trials will require a careful examination of side effects, important especially in long-term use. For p110a, the cancer-specific mutations offer a solution to this potential problem: the identification PI3K in oncogenic cellular transformation L Zhao and PK Vogt and development of mutant-specific inhibitors. These could interfere with the oncogenic versions of p110a and leave the important normal functions of wild--type p110a untouched. The genetic and biochemical data on the p110a mutants suggest that mutantspecificity could be attainable. A crystal structure of the mutant proteins would provide decisive guidance in this effort.
